BioSpace News Archive

- Collaboration combines Senti Bio’s leading-edge gene circuit technology platform and high-throughput synthetic promoter design capabilities with Spark Therapeutics’ investigational gene therapies targeting the central nervous system, eye or liver -

– Appointment strengthens leadership team as the Company readies for potential global odevixibat launch and progresses multiple clinical development programs – – Deep experience spanning drug development, manufacturing, quality and supply chain

Quartesian, a multinational Clinical Research Organization serving the biopharmaceutical and medical device industries, announced a multi-year agreement with a leading portfolio medical technology company.

Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a biotech innovation company focused on improving the health of the immune system, today announced that Sunny Uberoi has joined the organization as its Chief Communications Officer.

Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2021 financial results on Tuesday, May 4th, before the market opens. A conference call has been scheduled to discuss this information on Tuesday, May 4th, at 9:00 a.m. ET.

Cardinal Health was awarded a $57.8 million contract, including options that if exercised by the U.S. Department of Health and Human Services could reach $91.6 million, for the storage and distribution of 80,000 pallets of personal protective equipment to support the Strategic National Stockpile, part of the Office of the Assistant Secretary for Preparedness and Response within HHS.

Datos Health, a leader in remote care automation, today announced its collaboration with Amgen, one of the world’s leading independent biotechnology companies, on a new study to evaluate the potential impact of digital health data to improve therapy in heart failure.

NTX-001 is a potentially transformative adjunctive treatment for peripheral nerve injuries, using a propriety system for the reconnection of severed nerves. Neuraptive plans to conduct a Phase 2 Multicenter, Randomized, Controlled Study Evaluating the Safety and Efficacy of NTX-001 versus Standard of Care in Treatment and Prevention of Facial Paralysis Requiring Surgical Repair.

- SYNB1618 demonstrates proof of mechanism and phenylalanine (Phe) consumption in GI tract of healthy volunteers - - SYNB1618 Phase 2 study in patients with PKU ongoing -

LARVOL , leading provider of data and intelligence solutions for the pharmaceutical and biotech industry, today announced the launch of VIEW , the first curated social listening and sentiment analysis platform focused on Twitter-verified oncologists